



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PATENT

1616

**Applicant(s):** Sheryl Smith al.

**Examiner:** Unassigned

**Serial No.:** 10/566,559

**Group:** Unassigned

**Filed:** January 31, 2006

**Docket:** 1181-19 PCT US

**For:** ALPHA 4 BETA 2 DELTA  
GABA-A RECEPTORS AS A  
STRATEGY FOR PMS AND ALCOHOLISM

**Dated:** November 30, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to Applicants duty of disclosure, the information listed in the attached Form PTO-1449 is brought to the attention of the Examiner. Copies of the listed publications are submitted herewith.


The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 30, 2006.

Dated: November 30 2006

  
Ann R. Pokalsky

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./


information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Inasmuch as this Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits, no fee is due.


Nevertheless, please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 04-1121. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 04-1121 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

  
Ann R. Pokalsky  
Registration No.: 34,697  
Attorney for Applicants

DILWORTH & BARRESE, LLP  
333 Earle Ovington Boulevard  
Uniondale, New York 11553  
Tel. No. (516) 228-8484  
Fax No. (516) 228-8516  
ARP/ml

	Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1181-19 PCT US	SERIAL NO. 10/566,559
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANTS Smith et al.	
			FILING DATE January 31, 2006	GROUP ART UNIT <del>Unassigned</del> 1649

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		2002/0115611 A1	08/22/2002	Tallman et al.			
		2003/0138776 A1	07/24/2003	Goldman et al.			
		5,189,064	02/23/1993	Blum et al.			

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

			Sundstrom-Poromaa et al., (July 2002), "Hormonally Regulated $\alpha$ , $\beta_2\delta$ GABA <sub>A</sub> Receptors Are A
			Alcohol", <i>Nature Neuroscience</i> 5:8 721-722.

EXAMINER /Kimberly Ballard/	DATE CONSIDERED 08/13/2009
--------------------------------	-------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449 [6-4])

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./